ESALF News and Press, Eisai Co Ltd

Eisai Announces Strategic Investment Supported by the UK Government's LSIMF TOKYO, June 17, 2026 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced a strategic investment supported by the UK Government under the Life Sciences Innovati...

2026-05-26 08:11:55 ET Last time I wrote about Biogen Inc. ( BIIB ) was at the end of 2025 , in the article " Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge ."... Read the full article on Seeking Alpha For further details see: Leqembi Is...

2026-05-25 10:47:04 ET Eisai Co., Ltd. (ESAIY) Analyst/Investor Day May 25, 2026 3:00 AM EDT Company Participants Keisuke Naito - Representative Corporate Officer, EVP, COO & Chief Growth Officer Katsutoshi Ido - VP, Chief Scientific Officer & Head of DHBL Discov...

Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026 TOKYO, May 21, 2026 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the presentation of clinical research across its on...

2026-05-15 12:50:46 ET Eisai Co., Ltd. (ESAIY) Q4 2026 Earnings Call May 15, 2026 3:00 AM EDT Company Participants Takuya Oyama - Vice President, Chief Financial Officer & Chief IR Officer Haruo Naito - CEO, Representative Corporate Officer & Director Katsu...

2026-05-13 10:57:05 ET More on Eli Lilly Eli Lilly: 'Strong Buy' Raised Revenue Guidance By $2 Billion For 2026 And Label Expansions Eli Lilly: No Big Gap To Competition Eli Lilly and Company 2026 Q1 - Results - Earnings Call Presentation FDA asks for feedbac...

2026-05-08 02:52:33 ET More on Biogen Biogen Inc. (BIIB) Q1 2026 Earnings Call Transcript Biogen Inc. 2026 Q1 - Results - Earnings Call Presentation Revisiting Eisai And Biogen's Leqembi Data For Alzheimer's Disease Biogen outlines Apellis deal impacts with $...

2026-04-29 06:34:30 ET More on Biogen Revisiting Eisai And Biogen's Leqembi Data For Alzheimer's Disease Biogen Inc. (BIIB) Discusses Proposed Acquisition of Apellis and Strategic Growth Objectives Transcript Biogen Inc. (BIIB) Discusses Proposed Acquisition of Apell...

2026-04-21 10:48:14 ET A recent Cochrane review finds anti-amyloid antibody drugs like Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla offer only marginal cognitive and functional benefits for Alzheimer’s patients. Given high costs, risks, and minimal eff...

Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC) TOKYO and RAHWAY, N.J., Apr 21, 2026 - (JCN Newswire) - Merck & Co., Inc., Ra...